Proteolysis in human breast cancer

被引:60
作者
Garbett, EA [1 ]
Reed, MWR
Stephenson, TJ
Brown, NJ
机构
[1] N Tees Gen Hosp, Professorial Surg Unit, Stockton On Tees TS19 8PE, England
[2] Cent Sheffield Univ Hosp, Dept Surg, Sheffield S10 2JF, S Yorkshire, England
[3] Cent Sheffield Univ Hosp, Dept Histopathol, Sheffield S10 2JF, S Yorkshire, England
[4] Univ Sheffield, Dept Surg & Anaesthet Sci, Sheffield, S Yorkshire, England
来源
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY | 2000年 / 53卷 / 02期
关键词
breast cancer; matrix metalloproteinases; metastasis;
D O I
10.1136/mp.53.2.99
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background-The process of proteolysis is important at several stages of the metastatic cascade. A balance between the expression of the genes encoding endogenous proteinases and inhibitors exists and when the production of proteinases exceeds that of inhibitors proteolysis occurs. Aims-To determine whether differences in the profile and activity of proteinases and inhibitors exist within breast tumour tissue (n = 51), surrounding background breast tissue (n = 43), normal breast tissue from breast reduction mammoplasty operations (n = 10), and cells of the breast cancer cell line, MCF-7. Methods-Proteinase (matrix metalloproteinase 1 (MMP-1), MMP-2, MMP-3, MMP-9, urokinase-type plasminogen activator (uPA), and tissue-type PA (tPA)) and inhibitor (tissue inhibitor of metalloproteinases; TIMP-1 and TIMP-2) expression and proteinase activity were compared using substrate zymography, western blotting, immunohistochemistry, and quenched fluorescent substrate hydrolysis. Results-The presence of all proteinases and inhibitors was greater in breast tumour tissue when compared with all other types of breast tissue (p < 0.05). The activity of total MMMPs as determined by quenched fluorescent substrate hydrolysis was also greater in breast tumours (p < 0.05). Conclusion-There is increased proteolysis in human breast tumours when compared with other breast tissues.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 30 条
[1]  
BARAMOVA E, 1995, CELL BIOL INT, V19, P239
[2]  
BARRETT AJ, 1995, METHOD ENZYMOL, V244, P1
[3]   PROGNOSTIC VALUE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) AND PLASMINOGEN-ACTIVATOR INHIBITORS PAI-1 AND PAI-2 IN BREAST CARCINOMAS [J].
BOUCHET, C ;
SPYRATOS, F ;
MARTIN, PM ;
HACENE, K ;
GENTILE, A ;
OGLOBINE, J .
BRITISH JOURNAL OF CANCER, 1994, 69 (02) :398-405
[4]  
Brown CJ, 1996, J CLIN PATHOL-CL MOL, V49, pM331
[5]   EXPRESSION OF ACTIVATED GELATINASE IN HUMAN INVASIVE BREAST-CARCINOMA [J].
BROWN, PD ;
BLOXIDGE, RE ;
ANDERSON, E ;
HOWELL, A .
CLINICAL & EXPERIMENTAL METASTASIS, 1993, 11 (02) :183-189
[6]   Metalloproteinase inhibitors and the prevention of connective tissue breakdown [J].
Cawston, TE .
PHARMACOLOGY & THERAPEUTICS, 1996, 70 (03) :163-182
[7]  
CLAVEL C, 1992, B CANCER, V79, P261
[8]   ACTIVITY OF TYPE-IV COLLAGENASES IN BENIGN AND MALIGNANT BREAST DISEASE [J].
DAVIES, B ;
MILES, DW ;
HAPPERFIELD, LC ;
NAYLOR, MS ;
BOBROW, LG ;
RUBENS, RD ;
BALKWILL, FR .
BRITISH JOURNAL OF CANCER, 1993, 67 (05) :1126-1131
[9]   UROKINASE PLASMINOGEN-ACTIVATOR AND PROGNOSIS IN BREAST-CANCER [J].
DUFFY, MJ ;
REILLY, D ;
OSULLIVAN, C ;
OHIGGINS, N ;
FENNELLY, JJ .
LANCET, 1990, 335 (8681) :108-108
[10]   ASSAY OF MATRIX METALLOPROTEASES TYPE-8 AND TYPE-9 BY ELISA IN HUMAN BREAST-CANCER [J].
DUFFY, MJ ;
BLASER, J ;
DUGGAN, C ;
MCDERMOTT, E ;
OHIGGINS, N ;
FENNELLY, JJ ;
TSCHESCHE, H .
BRITISH JOURNAL OF CANCER, 1995, 71 (05) :1025-1028